Background-Percutaneous pulmonary valve implantation (PPVI) is a safe, less invasive alternative to surgical valve replacement for the congenital heart disease patient with right ventricular (RV) outflow tract dysfunction. The aim of this study was to determine whether reverse RV remodeling after PPVI was persistent in the longer term and whether timing of PPVI influenced outcomes. Methods and Results-Consecutive patients from the pediatric and adult congenital heart disease programs were enrolled.
A cquired right ventricular (RV) outflow tract stenosis and pulmonary regurgitation after conduit replacement often complicate the long-term course of the congenital heart disease patient. As such, patients with conduit dysfunction require repeat open-heart surgery for pulmonary valve replacement. In this regard, several series have demonstrated favorable short-term outcomes after percutaneous pulmonary valve implantation (PPVI) in the pediatric population. [1] [2] [3] [4] [5] [6] Whether the timing of valve replacement affects RV remodeling is an unanswered question, with some units advocating early intervention even in the asymptomatic individual to maximize the effects on RV form and function. [7] [8] [9] This study examines the intermediate-term effect of PPVI on RV size, function, and aerobic exercise capacity and the influence of age at intervention on these variables.
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Methods
Patient Population and Data Collection
All patients who underwent Melody valve (Medtronic Inc, Minneapolis, MN) PPVI at the Hospital for Sick Children and Toronto General Hospital, Toronto, Ontario, between October 2005 and October 2011 were enrolled. Research Ethics Board approval was obtained at both institutions and informed consent obtained. Information gathered retrospectively from the medical charts included echocardiographic, radiographic, exercise testing, and cardiac MRI (cMRI) findings. Investigations were obtained within 3 months before the index procedure and after implant: echocardiography on 1 day, 3 and 6 months, and yearly thereafter, an exercise test and chest x-ray after 3 months and biyearly, and cMRI within Pulmonary Valve Implants: Time-Related Outcomes 1 year and then every 2 to 3 years. Hemodynamic data were measured at the index procedure. All available clinical data points were analyzed. Late outcomes assessed included exercise and aerobic capacity, ventricular function and size, degree of pulmonary regurgitation, and RV to pulmonary artery (PA) pressure gradients. Out-of-province patients were contacted (n=6) and their reports requisitioned from referral centers.
Echocardiography
Two-dimensional transthoracic echocardiography was performed on a Phillips IE-33 (Andover, Massachusetts) machine using accepted methods, 2,10 with a standardized clinical protocol performed by a research sonographer. Data were retrieved from clinical reports with missing or outlying data points reviewed by 1 of the authors (S. Borik). RV enddiastolic (RVED) dimension and left ventricular (LV) ejection fraction were measured using m-mode in the parasternal short axis cut of the ventricles 2 and RV systolic pressure (RVSp) estimated using continuous wave Doppler from the tricuspid regurgitation jet velocity plus 5 mm Hg. Z-scores were calculated using accepted pediatric values. 11 RV outflow tract gradient was calculated using continuous wave Doppler on parasternal views. RV function was evaluated as a qualitative measure integrating all echocardiographic views and scored: 1, moderate to severely reduced function; 2, mildly reduced function; or 3, good function. 12 The degree of pulmonary insufficiency (PI) was evaluated by comparing the regurgitant jet width in the parasternal long and short axis views to the pulmonary valve annulus diameter and scored: 0, none; 1, trivial (jet width ≤1/3 of the pulmonary valve annulus); 2, mild (≥1/3 but ≤1/2 of the pulmonary valve annulus); 3, moderate (≥1/2 but less than the pulmonary valve annulus and regurgitation beginning in the pulmonary trunk), or 4, severe insufficiency (jet width equal to the pulmonary valve annulus with regurgitation seen in the branch pulmonary arteries). 2
MRI
Cardiac MRI was performed on a 1.5 Tesla Avanto MRI system (Siemens Medical Solutions, Erlangen, Germany) 2 using a standard protocol and was reviewed by a cMRI specialist (A. Crean) blinded to the study objectives. ECG-gated anatomic imaging of the heart was acquired using static and cine steady state free procession in the 2-, 3-, and 4-chamber views, short and long axis planes, and the RV outflow tract. Cine phase contrast velocity mapping of the ascending and descending aorta, main and branch pulmonary arteries, and superior caval and pulmonary veins were obtained for blood flow assessment. 2 Pulmonary regurgitant fraction was calculated as percent backward flow over forward flow in the right outflow tract and main pulmonary artery. RV and LV volumes were assessed manually at end-diastole and systole (Mass Analysis and CV Flow, Medis Medical Imaging Systems, Leiden, the Netherlands) and ventricular ejection fraction calculated using standard formula. 
WHAT IS KNOWN
• Percutaneous pulmonary valve implantation is an effective alternative to open heart surgery in the congenital heart disease patient with right ventricular outflow tract dysfunction.
• Several published series have shown acute reductions in the outflow tract gradients and right ventricular pressures after percutaneous pulmonary valve implantation, along with favorable effects on ventricular volume, degree of pulmonary insufficiency, and exercise capacity, maintained at the 1-year mark.
WHAT THE STUDY ADDS
• Our large cohort of children and adults displays persistent hemodynamic and functional improvements after percutaneous pulmonary valve implantation, well into intermediate-term follow up (mean 4.5 years).
• Younger patients (≤16 years of age), implanted at lower right ventricular volumes, exhibit incremental improvements in ventricular size and function and maximal oxygen consumption.
• With a low reoperation rate of 10% at 5 years and the expanding possibilities of percutaneous reintervention, our study findings suggest considering percutaneous pulmonary valve implantation at a younger age and smaller right ventricular volumes. Pulmonary Valve Implants: Time-Related Outcomes
Cardiopulmonary Exercise Testing and Chest Radiographs
Metabolic exercise testing was performed on a programmable ramp ergometer (Ergometrics-800S, Ergoline, Bitz, Germany), recording endurance time, heart rate, blood pressure, and maximal workload. 2 Respiratory data were analyzed for maximal oxygen consumption and anaerobic threshold as an average over 20 s (Max-1, Physio-Dyne Instrument Corporation, Quogue, New York). Raw exercise and metabolic data are presented with predicted values 13 for weight and body surface area. Digital chest radiograms were reviewed by one author (S. Borik) and graded for the presence of stent fracture(s) according to a previously accepted classification. 14
Statistical Analysis
Statistical analysis was performed using SAS Statistical Software version 9.1 (SAS Institute, Cary, NC). Data were described as mean±standard deviation, medians with a range, and frequency as appropriate. Analysis was performed using paired t-tests for comparative data sets before and after PPVI and Fisher exact test for descriptive data. Changes over time after PPVI were assessed using linear regression models (general estimating equations for parameter estimation), adjusted for repeated measures through an autoregressive covariance structure with measured parameters as the dependent variable and time since implantation as the independent variable. Differences in rate of change over time were assessed using the interaction with time term in the regression models. All sequential data were recorded and annualized changes calculated, correcting for the number of data points per patient. Freedom from reintervention is presented using Kaplan-Meier curves with log-rank test to compare freedom from reintervention between eras (before and after 2008). All analyses were adjusted for repeated measures to account for the number of examinations per patient. A P value of ≤0.05 was considered statistically significant. Analysis was performed on the full cohort as well as 2 subgroups based on median age, above and below 16 years of age. For change over time, early outcomes were designated Ao indicates aortic; cMRI, cardiac MRI; IQR, interquartile range; LV, left ventricle; LVEDVi, LV end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVi, LV end-systolic volume index; PA, pulmonary artery; PPVI, percutaneous pulmonary valve implantation; RV, right ventricle; RVED, RV end-diastolic; RVEDVi, RVED volume index; RVEF, RV ejection fraction; RVESVi, RV end-systolic volume index; RVSp, RV systolic pressure; and VO 2 , oxygen consumption.
*Hemodynamic data obtained during the PPVI procedure; late after the procedure was defined as >3 months for echocardiographic data; >12 months for exercise testing and cMRI data. †P1, before procedure vs early after the procedure. ‡P2, before procedure vs late after the procedure. Pulmonary Valve Implants: Time-Related Outcomes as occurring within the first 3 months after PPVI for hemodynamic and echo results and 1 year for cMRI and exercise data, based on the clinical protocol at our institutions. Ninety-six percent of patients had serial echocardiograms in follow-up, 75% had exercise testing and chest radiography, and 59% had cMRIs before and after the procedure (71% had cMRI in follow up).
Results
Patient Population
All 51 patients who underwent PPVI between October 2005 and October 2011 were reviewed and followed for a mean of 4.5±1.9 years (range 0.9-6.9 years, median 4.2 years; Table 1 ). Patients underwent an average of 5 echocardiograms (0-13, higher for earlier patients), 0.01 to 6.5 years after PPVI; and averaged 2 exercise tests (0-5), 0.2 to 6.4 years after implantation; 2 chest x-rays (0-6), 0.01 to 6.5 years after PPVI; and 1 cMRI (0-3), 0.01 to 6.2 years after the index procedure. One out-of-province patient was lost to follow-up and did not have a postprocedural echocardiogram but was clinically well. The mean time interval between the index procedure and the first cMRI was 0.9 years (range 0.4-1.2 years, median 0.6 years). 
Early Results
All patients exhibited immediate hemodynamic improvement after PPVI, including significant decreases in RV to PA pressure gradient, RVSp, and RV to systemic pressure ratio ( Table 2 ). There was no statistical improvement in exercise variables early after implantation. From cMRI data, the indexed RV end-diastolic volumes (RVEDVi; P=0.06) and the ratio between RV and LV indexed volumes (P=0.004) decreased on the first postprocedural cMRI, whereas there was no change in LV functional parameters.
Late Results
RV functional parameters did not change significantly in later follow-up ( Table 2 ; Figure 1 ), with the reduction of the RVEDVi (cMRI) persistent (117±37 mL/m 2 ; P=0.07). The RV to PA pressure gradient and the RVSp remained lower than before the procedure (P<0.001) and persisted in late followup, with no patient developing severe PI ( Figure 2 ). Early improvements seen in RV volumes and function were less pronounced through late follow-up, although overall they remained improved from values before PPVI ( Figure 1 ). Assessment of annualized changes after the index procedure did not disclose any clinically significant differences. Absolute maximal and percent-predicted oxygen consumption was significantly improved in late follow up (Table 2; Figure 3 ), as were exercise duration and peak heart rate. Total work performed improved in follow-up; however, there was not a statistically significant increase in percent-predicted values.
Outcomes by Age at Index Procedure
A younger age at the index procedure was associated with a smaller RVED dimension (−0.71±0.21 cm per decade of age and z-score, −1.29±0.36 per decade age), both P<0.001 at the first assessment after PPVI. Other variables such as the RVSp to systemic pressure ratio (−0.02±0.01 lower per decade, P=0.04), echocardiographic RV function (0.25±0.09 points higher per decade, P=0.008), and cMRI LV ejection fraction (3.86±1.02% higher per decade, P<0.001) were noted to be better statistically, but of unclear clinical significance. Younger patients at intervention also exhibited improved exercise capacity on the first cardiopulmonary stress test after PPVI, with higher maximal oxygen consumption by 2.40±0.85 mL/kg/min per decade of age (P=0.005), a relationship that was not significant before the procedure (Table 3) . Percent-predicted exercise values were also higher in younger patients, including percent-predicted VO 2 at anaerobic threshold (higher by 13.6±6.0% per decade of age [P=0.02]) and percent-predicted maximal VO 2 (3.8±1.9% per decade of age [P=0.05]).
In an attempt to determine whether there was a favorable age for valve implantation, serial post-PPVI measures were compared in patients above and below the median cohort age of 16 years ( Table 4 ). The 2 age groups did not differ significantly in demographic parameters, criteria for intervention, or RV volumes (Table 3) . After the procedure, the younger aged group displayed a smaller RV size and better biventricular function on sequential echocardiograms and cMRI. Additionally, RV size was smaller in follow-up in the younger group with a gradual, but nonsignificant decrease in RVEDVi and a statistically significant decline in the ratio of RVEDV/LVEDV compared with a gradual increase in these parameters in the older group (P=0.10 and 0.05, respectively). Furthermore, the younger patients displayed a trend toward better RV function on cMRI in late follow up (RVEF 50±7% in those ≤16 years versus 41±12% in the older group, P=0.07; Table 4 ) and statistically significant better RV function on echo (2.8±0.5 or good to mildly reduced RV function for those ≤16 years versus 1.9±0.9, mildly to moderately reduced RV function in those >16 years; P<0.001).
Time to Reintervention
Freedom from reintervention (percutaneous or surgical) was 87% and 68% at 3 and 5 years, and freedom from reoperation was 90% (Figure 4 ). These included 2 RV to PA conduit replacements, 1 pulmonary valve replacement, 1 aortic valve and root replacement and pulmonary homograft implantation for infectious endocarditis, and an arterial switch operation and occurred in the first 14 patients who underwent valve implantation. The patient with endocarditis had a common arterial trunk and presented 5 years after PPVI with multiple aortic root vegetations and vegetation on the implanted valve (Gram-positive cocci).
Freedom from reintervention was 100% at 2 years for all patients since 2008 (Figure 4 ). Seven patients (14%) underwent percutaneous reintervention at 3.6±2.1 (0.3-6.0) years after the index procedure, including 3 revalving (Melodywithin-Melody), 2 Sapien (Edwards Lifesciences Corp, Irvine Ca) valve implantations within the Melody valve, and 2 balloon dilations of the Melody valve. In most of these cases, reintervention was caused by restenosis and RV hypertension.
Eighteen percent of patients had evidence of minor (type 1) stent fractures on digital chest radiography, and 3% exhibited stent facture with loss of stent integrity. Of these patients, 63% required reintervention during the study period versus 23% without a stent fracture (P=0.05). Eighty-eight percent of fractures were in patients implanted (before 2008), with only a quarter of these having been prestented. However, the correlation between prestenting and the absence of stent fracture was not statistically significant (P=0.06), nor was there a correlation between age and the presence of a stent fracture.
Factors Associated With Improved Outcomes
Improved maximal VO 2 and percent-predicted maximal VO 2 were significantly associated with a younger age at the index procedure, lower preimplantation right-sided pressures, and better ventricular function and aerobic capacity before implantation ( Table 5 ). Melody implantation within a preexisting stent was also associated with an improved aerobic result and with better biventricular ejection fractions by cMRI after the procedure (Tables 5 and 6 ). Preparing the conduit for implantation was associated with a higher LV ejection fraction (5%±2%, P=0.006), better RV function (0.6%±0.2 points, P<0.001), a smaller RV (−0.8±0.3 cm, P=0.007), and lower RVSp (−9±3 mm Hg, P=0.01, echocardiographic), early after implantation, compared with those not stented. However, prestenting was not associated with a lower RV to PA pressure gradient. Interestingly, implantation within a homograft showed considerable advantage in aerobic capacity to that in a bioprosthetic valve. Furthermore, younger patients who had higher aerobic capacity, smaller ventricular volumes, and preserved function before implantation had better functional results for RV and LV ejection fractions (cMRI) after implantation (Table 6 ).
Discussion
PPVI has become an accepted, less invasive alternative to open heart surgery for the congenital heart disease patient with RV outflow tract dysfunction in both pediatric and adult populations. Several groups, including our own, have shown favorable short-term results after PPVI with the Melody valve. 1, 2, [16] [17] [18] [19] Bonhoeffer and colleagues, pioneers in the use of this technology, reported a series of 155 patients followed echocardiographically for a median 28.4 months (2.4 years) after valve implantation, 5 documenting a significant initial reduction in RVSp, pressure gradient across the pulmonary valve, improved valvar competence, and a 70% freedom from reintervention at 70 months. Our series further details the trajectory of these outcomes in the intermediate term (mean 4.5±1.9 years, median 4.2 years) from a large cohort with a wide age range at time of implantation. With a longer mean follow-up than previous series, we also document low reintervention rates and, importantly, low reoperation rates (10% over 5 years).
Our cohort also displayed a low (<2%) incidence of Melody valve-related infective endocarditis, in keeping with the experience of other large centers. 20 Additionally, the freedom from reintervention rate improved after 2008, due in part to better patient selection and enhanced technical improvements, such as valve implantation within a previously stented outflow tract. Earlier patients were also more likely to exhibit radiographic stent fracture, which was also associated with an increased rate of reintervention, in correlation with previous findings of the US Melody Valve Trial. 14 Although prestenting was associated with various functional advantages in our patients, there was no associated statistically significant reduction in the RV to PA gradient observed compared with those not stented. That there were a significant proportion of patients with bioprosthetic valves, and thus a limited internal hemodynamic office, may have influenced this finding. Prestenting did, however, show a trend for fewer radiographic stent fractures, and this, in turn, likely translated into lower rates of reintervention.
As noted by our group 2 and other investigators, 1,16 the present patient cohort showed an immediate hemodynamic improvement with a significant decrease in RVSp and the RV to PA pressure gradient invasively and by echocardiography. Unlike the US Melody Trial, 16 we noted an overall improvement in aerobic capacity, mainly late after implantation. However, when examining the results over time, an increase only in physical working capacity continued throughout the study period, whereas aerobic capacity reached a plateau in the longer term. Values adjusted for repeated measures. P1, difference between age groups for values; P2, difference between groups for change/year from the interaction term between years and age group in the regression models. Ao indicates aortic; cMRI, cardiac MRI; LV, left ventricle; LVEDVi, LV end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVi, LV end-systolic volume index; LVSVi, LV stroke volume index; PA, pulmonary artery; PPVI, percutaneous pulmonary valve implantation; RV, right ventricle; RVED, RV end-diastolic; RVEDVi, RVED volume index; RVEF, RV ejection fraction; RVESVi, RV end-systolic volume index; RVSp, RV systolic pressure; RVSVi, RV stroke volume index; and VO 2 , oxygen consumption. Pulmonary Valve Implants: Time-Related Outcomes This may be partly a result of the nature of this study population, which included all consecutive patients undergoing Melody valve implantation, most of whom had mixed disease with a significant degree of PI before the procedure. This element has been previously shown to be associated with a lack of improvement in exercise capacity after PPVI. 21, 22 The lack of aerobic improvement in follow-up may also be manifest because of later timing of valve implantation in RVs, which have lost their ability for persistent reverse remodeling, such that the initial positive effects gradually declined in follow-up.
Immediately after the procedure, confirming observations by other series, 6, 16 there was a decrease in RVEDVi and the ratio between RVEDV and LVEDV and a relative increase in LVEDVi. In this regard, the Lurz et al study from Great Ormond Street, London, examined the functional outcomes before, 1 month after, and 1 year after PPVI. 6 They showed favorable physiological changes at 1 month, which persisted at 1 year, but with no additional RV remodeling or functional improvement thereafter. To explore further changes over time, we assessed serial echocardiographic, exercise testing, and cMRI findings after the procedure. Our observations support those from Lurz's group, suggesting that most early changes seen after PPVI plateau in the following months and years after the procedure. Furthermore, followup in our cohort beyond the 1-year timeframe showed no further increase in aerobic capacity and biventricular function, accompanied by a gradual rise in RV volume, yet with a continued decrease in RVSp and RV to PA pressure gradient and an increase in physical work capacity. These late changes may reflect a modified unnatural history influenced predominately by the outflow diameter achieved, underlying cardiac anatomy, and the patient's age at the time of intervention. Despite this reduction or reversal in the slope of improvement, the functional and volumetric findings of the cohort at 5 years were for the most part significantly better in comparison with their status before the procedure. In addition, the low reoperation rate and high interventional success suggest that PPVI favorably influences the interventional history of this patient group and postpones the requirements for repeat surgery, whereas improving functional capacity, at least for the intermediate-term.
From observations in the pediatric cohort (at a younger age than most previous series), we noted that younger age at implantation was associated with improved biventricular function and aerobic capacity and a lower RV size after implantation compared with those intervened on at an older age. Although most functional and demographic characteristics were not different between the 2 cohorts, RVED dimension z-score and RVEDVi were lower in the younger patients before valve implantation (although nonsignificantly in the MRI data), suggesting that age at the procedure may be a surrogate for RV volume and for the duration of adverse loading conditions before valve implantation. In this regard, studies assessing the timing of surgical pulmonary valve replacement have suggested an improved ventricular recovery if valve competence is achieved at a younger age, at a RVEDVi ≈150 to 160 mL/ m 2 and before the development of RV dysfunction. [7] [8] [9] In a recent clinical assessment, Lee and colleagues from South Korea 9 analyzed a large group undergoing surgical pulmonary valve replacement for chronic PI and found that the optimal indexed RV volumes before surgery that lead to normalization of RV volumes and function after surgery were a RVEDVi of ≤163 mL/m 2 and end-systolic volume of ≤80 mL/m 2 . Previous groups have reported similar ranges of indexed end-diastolic RV volumes (150-170 mL/ m 2 ) and RVESVi (80-90 mL/m 2 ) before surgery for optimal ventricular rehabilitation. 7, 8, 23 Our results support these observations in part, suggesting younger patients whose RVs have not dilated to the extreme fare better than older patients with larger chamber dimensions and may have an enhanced potential for improvement in dimensions and function. Time will tell whether earlier and more aggressive rehabilitation of the right ventricle will be associated with more favorable clinical outcomes.
Improved aerobic capacity and biventricular function after PPVI were not solely associated with younger age, but also with a favorable hemodynamic profile before valve implantation, including a better aerobic capacity and ventricular function, previous stenting of the outflow tract, and a homograft rather than a bioprosthetic valve in the outflow tract. Although these factors did not significantly correlate with improved freedom from reintervention, they do suggest a patient profile, which may predict enhanced benefit from valve implantation. Additionally, the expanding possibilities of reintervention after PPVI, including revalving with a second percutaneous valve 5, 18 further deferring surgical intervention, provides a rationale for percutaneous valve implantation at younger ages and smaller RV volumes.
Limitations
The study is a retrospective observational study and suffers the drawbacks of retrospective data collection. The study group was small and only 59% of patients had a cMRI before and after implantation, limiting the power to assess events after intervention and perform a multivariate analysis. Additionally, although attempts were made to have a uniform follow-up protocol, it was variable such that the timing of functional changes had to be described arbitrarily into early and late and the number of follow up examinations per patient required statistical adjustment for repeat measures. Z-scores used for echocardiographic data were used for the entire cohort and have not been validated in adult patients and as such may be overestimated in larger patients. Finally, the study group was anatomically and physiologically heterogeneous, such that the indications for intervention were mixed, with too few pure PI or PS patients to separate into respective groups. However, all patients met the clinically accepted indications for intervention. Thus, we think our conjecture of the effect of RV volumes remains valid.
Conclusions
PPVI with the Melody valve has favorable intermediate-term results with low reoperation rates. The degree of some early improvements decreases in later follow up, yet the patients display significantly better functional and volumetric findings at 5 years, in comparison with their status before the procedure. Somewhat improved functional outcomes and RV dimensions were found in younger patients implanted at smaller RV volumes.
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